Occular is a visual prosthesis designed to restore both peripheral and central vision by incorporating a high count of electrodes directly into the visual cortex. It uses advanced stimulation patterns to achieve higher resolution. The device is based on flexible micro-electrode technology, minimizing scar tissue formation and enabling high resolution. The ultra-flexible electrode arrays, made from soft, biocompatible materials, move with the brain's tissue to minimize irritation and scar tissue formation.

ReVision, the company behind Occular, has developed a patented scalable insertion mechanism, allowing neurosurgeons to implant over 1000 electrodes efficiently. This technique has demonstrated long-term performance with minimal tissue damage in animal models. The device's advanced stimulation algorithm research aims to improve resolution, ensuring users can navigate daily life with image quality equivalent to a greyscale image of over 1000 pixels.

In 2024, ReVision Implant started safety and functionality testing on trained rhesus monkeys and sheep with external electronics. By the end of 2024, the IC should be available for pre-clinical testing.

Commercial Partner

• ReVision Implant

  Haasrode, Belgium